Every year, on 4 February, the World Health Organisation (WHO) promotes ways to ease the global burden of cancer.
Prof. Lukas Kenner has been appointed as member of the Research Advisory Committee of Prostate Cancer UK. In this position he will advise the Board of Trustees and Chief Executive of the Charity on its research strategies and policies, and to make recommendations as to which research grants the charity should support.
An entire decade of exciting research at the LBI-CR has passed since the institute was founded in September 2005. We generated significant research output as measured by publications, attraction of third party money, and seeing former members successfully embarking on international careers. This achievement was celebrated in November 2015 with a scientific meeting, which brought together some outstanding researchers, who have contributed to the success of the institute with their advice, support or collaboration.
A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins in November 2015.
Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) is a focused effort to develop protective and therapeutic HIV vaccines bringing together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA, including the LBI-CR.
Prof. Emilio Casanova, Prof. Lukas Kenner and Prof. Richard Moriggl gave their inaugural lectures in the "van Swieten hall" at the Medical University on September 22, 2015. These three LBG funded endowed professorships ensure sustainable integration of the expertise built up at the LBI-CR into the Partner universities.
Jan Pencik, PhD student at the Ludwig Boltzmann Institute for Cancer Research and the Clinical Institute of Pathology of the Medical University of Vienna is awarded the donated by Novartis Czech Discovery Award
The award is bestowed by a ten-member scientific jury to distinguished high-profile Czech researchers below 40 with outstanding contributions in the medical or pharmaceutical field, in particular innovative clinical, diagnostic and preventive approaches in oncology.
A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner of the Ludwig Boltzmann Institute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.
10 % of patients with acute myeloid leukemia (AML), a common form of blood cancer in adults, express a shortened form of the transcription factor C/EBPa that lacks a significant portion of the N-terminus of the protein. This short, mutant protein can induce leukemia development by preventing normal myeloid differentiation of blood cells. Through the investigation of specific interaction partners of the leukemia-associated, truncated variant of C/EBPa, the research group of Giulio Superti-Furga, Scientific Director at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, has gained new mechanistic insights into the molecular details of oncogenic transformation by C/EBPa mutant proteins. Florian Grebien, postdoctoral fellow in Superti-Furga´s team and since 2014 group leader at the Ludwig Boltzmann Institute for Cancer Research, found that the short, leukemic C/EBPa mutant can exert its oncogenic functions through a selective interaction with Wdr5, a critical constituent of histone-methyltransferase complexes that promote gene activation.
A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by William Tse at James Graham Brown Cancer Center,University of Louisville, in cooperation with Lukas Kenner from the LBI-CR has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.